Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

FTY720 in Patients With Primary Progressive Multiple Sclerosis (INFORMS)

This study has been completed.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: August 7, 2008
Last updated: April 13, 2015
Last verified: April 2015